Brief: Vertex Announces Marketing Authorization In Canada For Alyftrek
22/07/2025 19:46
July 23 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES MARKETING AUTHORIZATION IN CANADA FOR ALYFTREK, A ONCE-DAILY NEXT-GENERATION CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS Source text: ID:nCNWHMvvHa Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria